Calculating The Fair Value Of Marine & General Berhad (KLSE:M&G)
The projected fair value for Marine & General Berhad is RM0.24 based on 2 Stage Free Cash Flow to Equity
Current share price of RM0.25 suggests Marine & General Berhad is potentially trading close to its fair value
When compared to theindustry average discount of -76%, Marine & General Berhad's competitors seem to be trading at a greater premium to fair value
How far off is Marine & General Berhad (KLSE:M&G) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
View our latest analysis for Marine & General Berhad
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Levered FCF (MYR, Millions)
RM41.5m
RM31.6m
RM26.7m
RM24.1m
RM22.7m
RM22.0m
RM21.8m
RM21.9m
RM22.2m
RM22.7m
Growth Rate Estimate Source
Est @ -35.42%
Est @ -23.72%
Est @ -15.52%
Est @ -9.78%
Est @ -5.77%
Est @ -2.96%
Est @ -0.99%
Est @ 0.39%
Est @ 1.35%
Est @ 2.03%
Present Value (MYR, Millions) Discounted @ 15%
RM35.9
RM23.7
RM17.4
RM13.6
RM11.1
RM9.3
RM8.0
RM6.9
RM6.1
RM5.4
("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = RM137m
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 3.6%. We discount the terminal cash flows to today's value at a cost of equity of 15%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = RM23m× (1 + 3.6%) ÷ (15%– 3.6%) = RM198m
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= RM198m÷ ( 1 + 15%)10= RM47m
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is RM184m. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of RM0.3, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Marine & General Berhad as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 15%, which is based on a levered beta of 2.000. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Marine & General Berhad, there are three additional factors you should assess:
Risks: Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Marine & General Berhad (at least 1 which is concerning) , and understanding them should be part of your investment process.
Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
Other Environmentally-Friendly Companies: Concerned about the environment and think consumers will buy eco-friendly products more and more? Browse through our interactive list of companies that are thinking about a greener future to discover some stocks you may not have thought of!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the KLSE every day. If you want to find the calculation for other stocks just search here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions
Tandem Diabetes Care, Inc. recently announced a significant collaboration with Abbott Laboratories to integrate Abbott's upcoming dual glucose-ketone sensor with Tandem's insulin delivery systems. This and other collaborations, such as the agreement with Sequel Med Tech, align with Abbott's strategic focus on enhancing diabetes care. Abbott's shares rose 3% over the last quarter, aligning closely with broader market trends, which advanced 13% over the past year. The company's robust product approvals and partnerships, alongside positive market sentiment, likely reinforced investor confidence in Abbott's growth trajectory amid generally favorable market conditions. You should learn about the 1 possible red flag we've spotted with Abbott Laboratories. Find companies with promising cash flow potential yet trading below their fair value. The recent collaboration between Tandem Diabetes Care, Inc. and Abbott Laboratories to integrate Abbott's dual glucose-ketone sensor has the potential to enhance Abbott's market positioning in diabetes care. This partnership, along with other strategic agreements, could support revenue growth in Abbott's Diabetes Care segment, though challenges such as tariffs and VBP program impacts in China remain. Abbott's five-year total return, including share price and dividends, stands at 63.31%, showcasing strong longer-term performance, despite some earnings forecast pressure. In the past year, Abbott's shares have risen above the US Medical Equipment industry, which saw a return of 8.2%. This outperformance over a shorter time horizon indicates that investor confidence remains buoyant. However, the expectation of declining earnings over the next three years, with a 10.1% decrease per year, highlights forecast challenges. This contrasts with a forecasted revenue growth of 6.9% annually, which is slower than the broader US market growth rate of 8.6% per year. The current share price of US$133.06 reflects a modest 5.2% discount to the consensus analyst price target of US$140.41, suggesting a perception of fair valuation compared to expected earnings growth and projected revenue increases. Insights from our recent valuation report point to the potential undervaluation of Abbott Laboratories shares in the market. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Vertiv Holdings Co (NYSE:VRT) Unveils AI-Ready Cooling Architecture For NVIDIA GB300 NVL72 Platform
Vertiv Holdings Co recently introduced an energy-efficient 142kW cooling and power reference architecture for the NVIDIA GB300 NVL72 platform, which aligns with broader trends driving technology innovation in data centers. Over the past quarter, Vertiv's stock price rose by 27%, a significant move partially supported by this product release. This rise contrasted with a more modest market uptick where indices like the S&P 500 and Nasdaq saw less dramatic increases, buoyed by benign inflation data and easing U.S.-China trade tensions. Vertiv's innovative strategies clearly supported its positive stock performance during this period. We've identified 2 possible red flags with Vertiv Holdings Co and understanding the impact should be part of your investment process. The latest GPUs need a type of rare earth metal called Neodymium and there are only 24 companies in the world exploring or producing it. Find the list for free. Vertiv Holdings Co's recent introduction of energy-efficient cooling and power solutions aligns well with its strategic focus on AI and data centers, potentially boosting future revenue and earnings. Over a remarkable three-year period, Vertiv's total shareholder return was very large at 1062.27%, reflecting favorable investor sentiment and strong business execution. Despite posting a compelling annual return, Vertiv shares underperformed the US Electrical industry, which saw a 24% increase over the past year. However, Vertiv has outpaced the broader US market, which returned 12.8% over the same period, underlining its robust performance. The collaboration with NVIDIA is likely to reinforce Vertiv's growth trajectory by catalyzing revenue growth through AI infrastructure projects. Analysts forecast a significant upward trend, with revenues expected to rise to approximately $12.2 billion by 2028. While the company's current share price is US$93.48, it remains below the consensus price target of US$108.14, indicating potential room for upside as the market adjusts to revised forecasts. Gain insights into Vertiv Holdings Co's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:VRT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Donaldson Company (NYSE:DCI) Will Pay A Larger Dividend Than Last Year At $0.30
The board of Donaldson Company, Inc. (NYSE:DCI) has announced that the dividend on 30th of June will be increased to $0.30, which will be 11% higher than last year's payment of $0.27 which covered the same period. The payment will take the dividend yield to 1.5%, which is in line with the average for the industry. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. We like to see a healthy dividend yield, but that is only helpful to us if the payment can continue. However, Donaldson Company's earnings easily cover the dividend. This means that most of its earnings are being retained to grow the business. The next year is set to see EPS grow by 49.4%. If the dividend continues along recent trends, we estimate the payout ratio will be 25%, which is in the range that makes us comfortable with the sustainability of the dividend. See our latest analysis for Donaldson Company The company has an extended history of paying stable dividends. The dividend has gone from an annual total of $0.66 in 2015 to the most recent total annual payment of $1.08. This implies that the company grew its distributions at a yearly rate of about 5.0% over that duration. The growth of the dividend has been pretty reliable, so we think this can offer investors some nice additional income in their portfolio. Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Donaldson Company has seen EPS rising for the last five years, at 9.5% per annum. With a decent amount of growth and a low payout ratio, we think this bodes well for Donaldson Company's prospects of growing its dividend payments in the future. Overall, a dividend increase is always good, and we think that Donaldson Company is a strong income stock thanks to its track record and growing earnings. The company is easily earning enough to cover its dividend payments and it is great to see that these earnings are being translated into cash flow. All of these factors considered, we think this has solid potential as a dividend stock. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Companies that are growing earnings tend to be the best dividend stocks over the long term. See what the 8 analysts we track are forecasting for Donaldson Company for free with public analyst estimates for the company. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
